Abstract | BACKGROUND: METHODS: This randomised, open-label, phase 3 trial was done at 209 sites across 23 countries. Eligible patients were adults with untreated ES-SCLC, with WHO performance status 0 or 1 and measurable disease as per Response Evaluation Criteria in Solid Tumors, version 1.1. Patients were randomly assigned (in a 1:1:1 ratio) to durvalumab plus platinum- etoposide; durvalumab plus tremelimumab plus platinum- etoposide; or platinum- etoposide alone. All drugs were administered intravenously. Platinum- etoposide consisted of etoposide 80-100 mg/m2 on days 1-3 of each cycle with investigator's choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle). Patients received up to four cycles of platinum- etoposide plus durvalumab 1500 mg with or without tremelimumab 75 mg every 3 weeks followed by maintenance durvalumab 1500 mg every 4 weeks in the immunotherapy groups and up to six cycles of platinum- etoposide every 3 weeks plus prophylactic cranial irradiation (investigator's discretion) in the platinum- etoposide group. The primary endpoint was overall survival in the intention-to-treat population. We report results for the durvalumab plus platinum- etoposide group versus the platinum- etoposide group from a planned interim analysis. Safety was assessed in all patients who received at least one dose of their assigned study treatment. This study is registered at ClinicalTrials.gov, NCT03043872, and is ongoing. FINDINGS: Patients were enrolled between March 27, 2017, and May 29, 2018. 268 patients were allocated to the durvalumab plus platinum- etoposide group and 269 to the platinum- etoposide group. Durvalumab plus platinum- etoposide was associated with a significant improvement in overall survival, with a hazard ratio of 0·73 (95% CI 0·59-0·91; p=0·0047]); median overall survival was 13·0 months (95% CI 11·5-14·8) in the durvalumab plus platinum- etoposide group versus 10·3 months (9·3-11·2) in the platinum- etoposide group, with 34% (26·9-41·0) versus 25% (18·4-31·6) of patients alive at 18 months. Any-cause adverse events of grade 3 or 4 occurred in 163 (62%) of 265 treated patients in the durvalumab plus platinum- etoposide group and 166 (62%) of 266 in the platinum- etoposide group; adverse events leading to death occurred in 13 (5%) and 15 (6%) patients. INTERPRETATION: First-line durvalumab plus platinum- etoposide significantly improved overall survival in patients with ES-SCLC versus a clinically relevant control group. Safety findings were consistent with the known safety profiles of all drugs received. FUNDING: AstraZeneca.
|
Authors | Luis Paz-Ares, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Oleksandr Voitko, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Kazarnowicz, György Losonczy, Nikolay V Conev, Jon Armstrong, Natalie Byrne, Norah Shire, Haiyi Jiang, Jonathan W Goldman, CASPIAN investigators |
Journal | Lancet (London, England)
(Lancet)
Vol. 394
Issue 10212
Pg. 1929-1939
(11 23 2019)
ISSN: 1474-547X [Electronic] England |
PMID | 31590988
(Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2019 Elsevier Ltd. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Immunological
- Antineoplastic Agents, Phytogenic
- durvalumab
- Etoposide
- Carboplatin
- Cisplatin
- tremelimumab
|
Topics |
- Aged
- Antibodies, Monoclonal
(administration & dosage, adverse effects)
- Antibodies, Monoclonal, Humanized
(administration & dosage)
- Antineoplastic Agents, Immunological
(administration & dosage, adverse effects)
- Antineoplastic Agents, Phytogenic
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
- Carboplatin
(administration & dosage, adverse effects)
- Cisplatin
(administration & dosage, adverse effects)
- Drug Administration Schedule
- Etoposide
(administration & dosage, adverse effects)
- Female
- Humans
- Lung Neoplasms
(drug therapy, mortality)
- Male
- Middle Aged
- Progression-Free Survival
- Small Cell Lung Carcinoma
(drug therapy, mortality)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|